Phase 1 N=10 Randomized Double-blind Basic Science

Opioid and Cannabinoid Interactions

Marijuana Usage · Opioid Use

Bottom Line

View on ClinicalTrials.gov: NCT03705559 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2025

Primary outcome: Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: Vaporized Marijuana (Drug); Opioid Agonist (Drug); Placebo (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Shanna Babalonis, PhD
Primary completion: Feb 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Subject-Rated Outcome - VAS Drug Liking	3; 53.33; 58.89; 38.78; 35.22; 48.67	—
SECONDARY Change in Oxygen Saturation	96.56; 96.44; 96.44; 96.44; 96.11; 96.22	—
SECONDARY Change in Respiration Rate	11.89; 11.44; 12.44; 11.22; 10.22; 10.89	—
SECONDARY Change in Systolic Blood Pressure	133.56; 134.06; 140.56; 136.33; 134.33; 138.11	—
SECONDARY Change in Diastolic Blood Pressure	89.44; 97.18; 94.92; 94.08; 91.78; 91.83	—

Summary

This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.

Eligibility Criteria

Inclusion Criteria

Healthy adults ages 18-50
Current non-medical use of opioids and marijuana

Exclusion Criteria

Physical dependence on opioids, alcohol benzodiazepines/sedative/hypnotics
Seeking treatment for drug use
Significant medical problems

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03705559). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.